According to informed sources, about half a dozen pharmaceutical companies are going to make a renewed offer to acquire the Swiss pharmaceutical company Mepha, belonging to the family of the late German billionaire Adolf Merckle. Among them will be selected by 2-3 companies, the sources said. The deal could reach more than 700 million Swiss francs (695 million U.S. dollars). Time frame for submission of final proposals are not set.
Among the bidders for the company as a major pharmaceutical producers and manufacturers of specialized generics, although the estimated potential buyers, such as France's Sanofi-Aventis, and Hungary's Gedeon Richter with offers to buy Mepha not previously performed. The U.S. generic company Watson Pharmaceuticals Inc also sat on the sidelines because of the complexity of work in Switzerland, where the approval of drugs differs from the process in the EU.
The representative of the family declined to comment Merkle. Mepha, sales of which in 2008 amounted to 379 million francs was offered for sale in August of this year Sales of the company carried out simultaneously with the sale of German pharmaceutical company, Ratiopharm, also belonging to the family Merkle.
Earlier, sources reported, at least 10 potential buyers Ratiopharm, including pharmaceutical and private investment companies. The deal varies, mostly within 2-2,5 billion euros (3-3,74 billion U.S. dollars). We recall that Adolf Merckle, committed suicide in January 2009, Ratiopharm put up for sale along with one of Europe's largest producers of cement company HeidelbergCement and farmdistribyutorskoy by Phoenix. Their sale is part of an agreement with creditors. However Mepha under this agreement does not fall.
No comments:
Post a Comment